A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation - Takeaways - MDSpire

A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation

  • By

  • Chenlu Hou

  • Yifan Zhang

  • Xiangqi Cao

  • Yonglan Tang

  • Ting Gao

  • Baoli Tang

  • Ying Zhu

  • Zhe Ruan

  • Ting Chang

  • June 3, 2026

  • 0 min

Share

  • 1

    Rituximab is an established treatment for myasthenia gravis but has variable efficacy across different patient populations.

  • 2

    The study included 117 patients who received low-dose rituximab and aimed to develop a predictive model for treatment efficacy.

  • 3

    Five key variables were identified for predicting minimal symptom expression: new-onset MG, baseline MG-ADL score, B lymphocyte proportion, prednisone dose, and immunotherapy timing.

  • 4

    The predictive model demonstrated moderate discriminative ability with an AUC of 0.777 and stratified patients into high- and low-probability groups.

  • 5

    The high-probability group had a 6.52-fold increased likelihood of achieving minimal symptom expression after 6 months of treatment.

Original Source(s)

A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation

  • by Chenlu Hou, Yifan Zhang, Xiangqi Cao, Yonglan Tang, Ting Gao, Baoli Tang, Ying Zhu, Zhe Ruan, Ting Chang

  • June 3, 2026

Related Content

Case Report: Tocilizumab in pediatric febrile infection-related epilepsy syndrome

Mechanisms and therapeutic advances of gut metabolites in the regulation of neuroimmune inflammatory diseases

Efficacy and safety of ozone autohemotherapy for zoster-associated pain: a meta-analysis and trial sequential analysis